Affy Shares Up 6.3 Percent After Firm Reports Need to Restate Certain Financial Reports | GenomeWeb
NEW YORK (GenomeWeb News) - Shares in Affymetrix were up 6.25, or $1.20, at $20.41 in mid-afternoon share after the company late yesterday said it would have to restate its financial results as far back as 1997 after an internal review into its stock-option granting practices turned up “certain documentation lapses.”
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.